Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Beigene Ltd ADR (NQ: BGNE ) 154.74 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 154.74 Bid (Size) 140.17 (1) Ask (Size) 159.98 (1) Prev. Close 154.74 Today's Range 154.74 - 154.74 52wk Range 126.97 - 225.23 Shares Outstanding 1,211,067,023 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer July 18, 2024 From BeiGene, Ltd. Via Business Wire Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio? June 30, 2024 10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com, Ecopetrol, International Paper, Micron. Via Benzinga Performance YTD -12.58% -12.58% 1 Month -0.88% -0.88% 3 Month +18.18% +18.18% 6 Month -1.20% -1.20% 1 Year -20.74% -20.74% More News Read More What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? June 17, 2024 Via Benzinga Evaluating BeiGene: Insights From 6 Financial Analysts April 24, 2024 Via Benzinga 4 Analysts Assess BeiGene: What You Need To Know March 27, 2024 Via Benzinga Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare June 15, 2024 Via Talk Markets BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 June 14, 2024 From BeiGene, Ltd. Via Business Wire BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From BeiGene, Ltd. Via Business Wire 7 Large-Cap Stocks That Can Jump 50% By 2025 May 29, 2024 Via InvestorPlace Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio? May 26, 2024 Via Benzinga Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings May 25, 2024 Via Talk Markets BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL May 24, 2024 From BeiGene, Ltd. Via Business Wire BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 May 14, 2024 From BeiGene, Ltd. Via Business Wire BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace BeiGene Reports First Quarter 2024 Financial Results and Business Updates May 08, 2024 From BeiGene, Ltd. Via Business Wire Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024) April 28, 2024 Via Benzinga BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report April 26, 2024 From BeiGene, Ltd. Via Business Wire Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting April 24, 2024 From BeiGene, Ltd. Via Business Wire HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday April 23, 2024 Via Benzinga BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer April 23, 2024 From BeiGene, Ltd. Via Business Wire Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal March 30, 2024 Via Talk Markets Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities March 23, 2024 Via Talk Markets Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session March 22, 2024 Via Benzinga Topics Stocks Exposures US Equities FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer March 15, 2024 Via Benzinga Exposures Product Safety BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 14, 2024 From BeiGene, Ltd. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.